Monthly Archives: May 2015

Imprime PGG-MAb Combination Therapy Achieves High Response Rate in Patients with Chronic Lymphocytic Leukemia

CHICAGO — May 31, 2015 — A combination of Biothera’s Imprime PGG and the monoclonal antibodies alemtuzumab and rituximab achieved responses in 13 of 14 (93%) patients with high-risk chronic lymphocytic leukemia, including nine (64%) complete responses. Results of this phase 1/2 study will be presented today at the American Society of Clinical Oncology (ASCO). Imprime PGG is an investigational cancer immunotherapy that directly modulates...

Read More


Integrated Safety Data from Two Phase 2 Cancer Studies Demonstrates Biothera’s Investigational Cancer Immunotherapy is Well Tolerated

CHICAGO — May 31, 2015 — A new, combined analysis of patient-level data from two randomized studies in non-small cell lung cancer provides further evidence that Biothera’s investigational immunotherapy Imprime PGG is safe and well tolerated, with adverse events generally consistent with complications of the disease and toxicities attributable to the cytotoxic drugs or monoclonal antibody therapies. Biothera presented the data yesterday at the American...

Read More


Biothera Presents Additional Data at ASCO on Durability and Characteristics of Response with Imprime PGG in Non-Small Cell Lung Cancer Study

CHICAGO — May 31, 2015 — Biothera’s investigational cancer immunotherapy Imprime PGG in combination with standard platinum-based doublet chemotherapy and the monoclonal antibody bevacizumab achieved rapid and lasting responses in patients with non-squamous non-small cell lung cancer (NSCLC). Tumor reduction was observed regardless of tumor burden (up to > 30 cm) or location of lesions at baseline (including lung, lymph nodes, adrenals, liver). These findings...

Read More


Biothera to Present New Data at the American Society of Clinical Oncology Annual Meeting

EAGAN, MN — May 28, 2015 — Biothera announced today that new data and insights for Imprime PGG, the company’s investigational cancer immunotherapy drug, will be featured in four presentations at the 2015 American Society of Clinical Oncology annual meeting May 29-June 2 in Chicago. Saturday, May 30; 8:00 am-11:30 am. Location: S Hall A: Abstract #3070. Poster Board Number #396Durability and Characteristics of Objective...

Read More


Biothera to Present Additional Data to the American Association of Immunologists on Imprime PGG’s Potential to Alleviate Tumor-mediated Immunosuppression

NEW ORLEANS — May 8, 2015 — Additional data showing Biothera’s investigational cancer immunotherapy Imprime PGG can alleviate tumor-mediated immunosuppression and potentially strengthen the body’s ability to recognize and kill tumor cells will be presented on Sunday at the American Association of Immunologists (AAI) annual meeting. Earlier this month at the American Association for Cancer Research, Biothera presented new research supporting the potential of Imprime...

Read More